M42 plans new Bahrain healthcare facility with 20 specialties, launches AI-powered platform
The Bahrain Bay development will be the group’s second healthcare facility in the country
21 October, 2026
TT
16
Healthcare major M42 plans to develop a multidisciplinary healthcare facility in Bahrain Bay through a joint venture with local partner HealthVision, expanding its specialist care network in the kingdom.
Mubadala Health Bahrain will offer 20 specialities, including six surgical inpatient specialities at launch, according to an announcement on Tuesday.
M42 signed an agreement with Bahrain’s Future Generations Reserve Fund to secure the location at its tower in Bahrain Bay. The announcement was made during the Abu Dhabi Future Health Summit.
The facility’s planned services include cardiology, oncology, orthopaedics, paediatrics and neurology, alongside longevity, precision medicine, genomics, artificial intelligence and wellness services.
It is expected to employ approximately 200 people, with a focus on recruiting and developing Bahraini talent.
M42 group CEO Dimitris Moulavasilisr said Bahrain remained part of the company’s regional expansion strategy.
The announcement did not disclose an investment value or opening date.
M42 also launched Ossi, a multi-agent AI clinical platform designed to reduce administrative work and give clinicians more time with patients. Built on Microsoft Azure infrastructure, it has been activated across seven M42 healthcare facilities in the UAE and Bahrain.
Its four initial agents draft clinical notes, retrieve and summarise medical records, support clinical queries and patient education, and suggest medical codes, with documentation and coding subject to review.
The multilingual platform integrates with existing electronic medical record systems. M42 says Ossi supports regional data governance requirements and incorporates safeguards for patient information security and privacy within clinical care workflows.
Mubadala Bio and Eli Lilly agreement
In other news, Mubadala Bio and Eli Lilly have agreed to develop local packaging and logistics operations for Lilly’s GLP-1 medicines in Abu Dhabi, expanding the emirate’s pharmaceutical supply-chain capabilities.
The collaboration, announced at the Abu Dhabi Future Health Summit, will be supported by a 125,000-square-metre site in KEZAD comprising packaging and warehousing facilities.
Activities will be introduced in phases, subject to technical, quality and regulatory requirements, according to an announcement published on Tuesday.
The agreement’s specified scope covers packaging and logistics. The announcement did not identify individual medicines to be packaged, disclose financial terms or provide a start date.
Nabil Daoud, president and general manager of Lilly’s Intercontinental Hub, said the agreement would strengthen the company’s long-term presence in the UAE.
Mubadala Bio said the partnership would support its efforts to expand pharmaceutical capabilities and connect Abu Dhabi with international medicine supply chains.
The announcement builds on the UAE’s leadership in advancing access to innovative medicines and strengthening personalised healthcare.
The Emirates Drug Establishment (EDE) approved Foundayo (orforglipron) for chronic weight management in April, making the UAE the second country in the world to register the medicine.
In Abu Dhabi, the treatment was introduced for eligible patients under the Personalised Weight Management Program, launched by the Department of Health – Abu Dhabi (DOH) and Abu Dhabi Public Health Centre (ADPHC) in June last year.
The UAE was an early launch market for Mounjaro (tirzepatide) in August 2022 following US FDA approval.


















